Compare Heron Therapeutics Inc (HRTX) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Wheaton Precious Metals Corp — how do they compare? Heron Therapeutics Inc trades at $0.38 (market cap $68.01M), while Wheaton Precious Metals Corp trades at $137.5 (market cap $61.17B). The key difference: Wheaton Precious Metals Corp is far larger — about 899.4× Heron Therapeutics Inc's market cap, and Wheaton Precious Metals Corp pays a 0.58% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Wheaton Precious Metals Corp for 66 Days on average.
| HRTX | WPM | |
|---|---|---|
Market Cap | $68.01M | $61.17B |
Volume | 1,891,941 | 1,092,361 |
Sector | Health | Basic Materials |
52-Week High | $1.49 | $165.72 |
52-Week Low | $0.27 | $94.37 |
Typical Hold Time | 35 Days | 66 Days |
Enterprise Value | $174.75M | $63.05B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
Wheaton Precious Metals (WPM) trades at $133.69, down 2.88% on the day, amid a bearish technical signal. The company reported record H1 2026 revenues and beat EPS estimates for three consecutive quarters, with strong profitability margins (gross margin 75.25%, net margin 64.66%). Recent news highlights a growth strategy targeting 1.2 million ounces of production by 2030 through an expanded deal pipeline, supported by a fully funded capital plan.
The outlook remains positive given robust earnings momentum and analyst consensus (80% buy ratings, $164.80 price target). Key risks include execution of growth targets and sensitivity to gold/silver prices. The stock offers exposure to precious metals with high margins but trades at premium valuations (P/E 29.94, P/S 19.36), requiring confidence in delivery of projected growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
